Members warn dissolution of newborn‑screening advisory committee risks lives; lawmakers press to reauthorize newborn screening program
Get AI-powered insights, summaries, and transcripts
Subscribe
Summary
Multiple members told the Energy and Commerce Subcommittee that dissolving the federal advisory committee that recommends additions to the newborn screening panel threatens a process that routinely identifies treatable, life‑threatening conditions in infants.
Multiple members used the Health Subcommittee hearing to press for swift action to reauthorize and restore federal support for newborn screening programs after members said the advisory committee that recommends conditions be added to the Recommended Uniform Screening Panel (RUSP) was dissolved without advance public notice.
Why it matters: Newborn screening identifies conditions at or shortly after birth that, if detected early, can be treated to prevent irreversible harm or death. Members said the federal panel that advises which conditions should be added to the RUSP — the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) — was recently disbanded, interrupting a process that helps states standardize screening and ensures that families nationwide benefit from early detection.
Representative Marc Veasey (D‑Texas) described the impact of newborn screening through a family example entered into the hearing record. He read an NBC News article about Jennifer McNary and her two sons: one, diagnosed with Duchenne muscular dystrophy (DMD) at age 3, died at 26; her second son, diagnosed at birth through screening, received early therapy and treatments that extended his mobility and preserved more function. “That’s the difference this committee makes,” Veasey said, calling the committee’s work “life or death for many families.”
Members and witnesses discussed a draft reauthorization bill described in the hearing as the Newborn Screening Saves Lives Reauthorization Act of 2025. Representative Kim Schrier (D‑Wash.) and other members emphasized the narrow, bipartisan origins of newborn screening programs and urged the committee to act to restore a functioning advisory process and ensure HHS provides the staffing and support necessary to evaluate and add conditions to the RUSP.
HRSA witnesses deferred detailed operational answers to the agency’s maternal and child health bureau, but members said they plan to pursue additional oversight and follow‑up. Representative Veasey entered the NBC piece dated April 17, 2025, into the congressional record during his remarks to illustrate how early screening can change outcomes for children with genetic conditions such as DMD.
What’s next: Members urged reestablishing ACHDNC or an equivalent advisory process and moving the newborn screening reauthorization bill forward. Several members said they would submit additional questions for the record and expect the committee to work quickly to restore the advisory capacity used for decades to add conditions to the national screening panel.
Ending: Lawmakers ended their remarks stressing urgency, noting that newborn screening saves thousands of lives each year and that sudden changes to the advisory process risk returning the United States to an uneven, state‑by‑state patchwork that would leave some infants without timely diagnosis and treatment.